Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Medicines Agency (EMA) has accepted to review Pfizer's experimental compounds, crizotinib and bosutinib's applications.
Subscribe to our email newsletter
Crizotinib is indicated as a treatment for patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC).
Bosutinib is indicated as a treatment for patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
Pfizer Oncology Europe president Andreas Penk said with the EMA submissions, they are one step closer to bringing two agents to patient populations in areas of significant unmet medical need.